Immunovant, Inc. (IMVT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Frank M. Torti M.B.A., M.D.
|
Executive Chairperson of the Board | 92.5k | -- | 1979 |
|
Dr. Eric Venker M.D., Pharm.D.
|
CEO & Director | 1.15M | -- | 1987 |
|
Mr. Tiago M. Girao CPA
|
Chief Financial Officer | 691.21k | -- | 1979 |
|
Ms. Melanie Gloria B.S.N.
|
Chief Operating Officer | 759.07k | -- | 1978 |
|
Dr. Jay S. Stout M.S., Ph.D.
|
Chief Technology Officer | 757.67k | -- | 1963 |
|
Mr. Christopher A. Van Tuyl Esq., J.D.
|
Chief Legal Officer & Corporate Secretary | 757.09k | -- | 1975 |
|
Ms. Christine Blodgett
|
Senior Vice President of Human Resources | -- | -- | -- |
|
Ms. Becky Merlina
|
Senior VP & Global Head of Quality | -- | -- | -- |
|
Ms. Yan Zheng M.S., Ph.D.
|
Senior Vice President of Biostatistics, Programming & Data Management | -- | -- | -- |
|
Ms. Sheetal Patel M.B.A., M.D., M.S.
|
Senior Vice President of Clinical Development | -- | -- | -- |
Immunovant, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 315
Description
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Corporate Governance
Upcoming Events
November 9, 2026 at 12:30 PM UTC
Immunovant, Inc. Earnings Date
